{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["63(7)"],"submitter":["Burggraaff CN"],"pubmed_abstract":["We aimed to determine the added value of baseline metabolic tumor volume (MTV) and interim PET (I-PET) to the age-adjusted international prognostic index (aaIPI) to predict 2-y progression-free survival (PFS) in diffuse large B-cell lymphoma. Secondary objectives were to investigate optimal I-PET response criteria (using Deauville score [DS] or quantitative change in SUV<sub>max</sub> [ΔSUV<sub>max</sub>] between baseline and I-PET4 [observational I-PET scans after 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered in 2-wk intervals with intensified rituximab in the first 4 cycles [R(R)-CHOP14]). <b>Methods:</b> I-PET4 scans in the HOVON-84 (Hemato-Oncologie voor Volwassenen Nederland [Haemato Oncology Foundation for Adults in the Netherlands]) r"],"journal":["Journal of nuclear medicine : official publication, Society of Nuclear Medicine"],"pagination":["1001-1007"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9258573"],"repository":["biostudies-literature"],"pubmed_title":["<sup>18</sup>F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study."],"pmcid":["PMC9258573"],"pubmed_authors":["Burggraaff CN","de Keizer B","van der Holt B","Eertink JJ","Zijlstra JM","Arens AIJ","HOVON Imaging Working Group and the HOVON Lymphoma Working Group","Pieplenbosch S","Lugtenburg PJ","Heymans MW","Wiegers SE","de Vet HCW","Boellaard R","Hoekstra OS"],"additional_accession":[]},"is_claimable":false,"name":"<sup>18</sup>F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.","description":"We aimed to determine the added value of baseline metabolic tumor volume (MTV) and interim PET (I-PET) to the age-adjusted international prognostic index (aaIPI) to predict 2-y progression-free survival (PFS) in diffuse large B-cell lymphoma. Secondary objectives were to investigate optimal I-PET response criteria (using Deauville score [DS] or quantitative change in SUV<sub>max</sub> [ΔSUV<sub>max</sub>] between baseline and I-PET4 [observational I-PET scans after 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered in 2-wk intervals with intensified rituximab in the first 4 cycles [R(R)-CHOP14]). <b>Methods:</b> I-PET4 scans in the HOVON-84 (Hemato-Oncologie voor Volwassenen Nederland [Haemato Oncology Foundation for Adults in the Netherlands]) r","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-22T10:10:06.169Z","creation":"2025-04-05T23:30:13.519Z"},"accession":"S-EPMC9258573","cross_references":{"pubmed":["34675112"],"doi":["10.2967/jnumed.121.262205"]}}